Effect of Cardiac Stem Cells on Left-Ventricular Remodeling in a Canine Model of Chronic Myocardial Infarction

Frederick G.P. Welt, MD; Robert Gallegos, MD, PhD; John Connell, MD, MPH; Jan Kajstura, PhD; Domenico D’Amario, MD, PhD; Raymond Y. Kwong, MD, MPH; Otavio Coelho-Filho, MD, MPH; Ravi Shah, MD; Richard Mitchell, MD, PhD; Annarosa Leri, MD; Lori Foley, CVT; Piero Anversa, MD; Marc A. Pfeffer, MD, PhD

Background—Regenerative medicine, including cell therapy, is a promising strategy for recovery of the damaged myocardium. C-kit–positive cardiac stem cells (CSCs) have been shown to improve myocardial function after ischemic injury in animal models and in early clinical experience. We used a chronic large animal model of myocardial infarction with substantial reductions in left-ventricular (LV) ejection fraction and adverse remodeling to examine the effect of late autologous CSC intramyocardial injection on long-term cardiac structure and function.

Methods and Results—Thoracotomy and ligation of the proximal left anterior descending artery, additional diagonal branches, and atrial biopsy for CSC culture were performed in canines. Baseline cardiac MRI was performed at 6 weeks postinfarct followed by repeat thoracotomy for randomization to intramyocardial injection of CSCs (n=13) or vehicle alone (n=6). At 30 weeks postmyocardial infarction, repeat MRI was performed. Data were analyzed using nonparametric tests (Wilcoxon signed-rank and rank-sum tests). In control animals, LV end-systolic volume and end-diastolic volume increased from 6 to 30 weeks (median and interquartile range, 51.3 mL [43.3–57.4] to 76.1 mL [72.0–82.4]; P=0.03 and 78.5 mL [69.7–86.1] to 99.2 mL [97.1–100.4]; P=0.03). Left-ventricular ejection fraction declined further (35.2% [27.9–38.7] to 26.4% [22.0–31.0]; P=0.12). In the cell-treated animals, this late adverse LV remodeling was attenuated (LV end-systolic volume, 42.6 mL [38.5–50.5] to 56.1 mL [50.3–63.0]; P=0.01 versus control). There was a nonsignificant attenuation in the increase in LV end-diastolic volume (64.8 mL [60.7–71.3] to 83.5 mL [74.7–90.8]; P=0.14 versus control) and LV ejection fraction change over time differed (30.5% [28.4–33.4] to 32.9% [28.6–36.9]; P=0.04 versus control).

Conclusions—Intramyocardial injection of autologous CSCs in a late phase model of chronic infarction resulted in less increase in LV end-systolic volume and preservation of LV ejection fraction. (Circ Heart Fail. 2013;6:99-106.)

Key Words: animal model ■ chronic heart failure ■ remodeling heart failure ■ stem cells

Regeneration and repair of myocardium through cell therapy offer the potential for recovery of function after ischemic injury in both the acute and chronic setting. Several unipotent and multipotent cell types, including human embryonic stem cells,1 C-kit–positive (c-kitpos) hematopoietic stem cells,2 CD34-positive cells,3 side population bone marrow cells,4 bone marrow mesenchymal stem cells,5 bone marrow mononuclear cells (BMCs),6 and resident cardiac progenitor cells,7,8 have demonstrated some cardiac regenerative capacity in animal models. Despite multiple studies in both animals and humans, many questions remain including what is the appropriate cell type, the best method of delivery, the correct timing of administration, and the mechanism and extent of functional improvement. Because the use of xenogenic cells in the majority of these studies limits the duration of observation, the durability of the effect has not received the same attention. This study was designed to utilize a canine model of chronic infarction with progressive adverse remodeling to examine the effects of intramyocardial autologous cardiac stem cell (CSC) injection on the late phase of adverse left ventricle (LV) remodeling.

Clinical Perspective on p 106

CSCs defined as c-kitpos cells isolated from cardiac tissue have been demonstrated to be self-renewing, clonogenic, and multipotent both in vitro and in vivo.4 CSCs have been shown to alleviate myocardial dysfunction in multiple animal studies when delivered after acute myocardial infarction (MI). These cells have been demonstrated to form

Received May 10, 2012; accepted November 13, 2012.

From the Brigham and Women’s Hospital, Boston, MA (F.G.P.W., J.C., J.K., R.Y.K., R.S., R.M., A.L., L.F., P.A., M.A.P.); The Ohio Heart and Vascular Center, Cincinnati, OH (R.G.); Catholic University of the Sacred Heart, Rome, Italy (D.D.A.); and State University of Campinas, Campinas, Sao Paolo, Brazil (O.C.-F.).

The online-only Data Supplement is available at http://circheartfailure.ahajournals.org/lookup/suppl/doi:10.1161/CIRCHEARTFAILURE.112.972273/DC1.

Correspondence to Frederick G.P. Welt, MD, Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA 02115. E-mail fwelt@partners.org

© 2012 American Heart Association, Inc.

Circ Heart Fail is available at http://circheartfailure.ahajournals.org

DOI: 10.1161/CIRCHEARTFAILURE.112.972273

99
new functional and contracting myocardium as well as new capillaries, arterioles, and large arteries.\(^9\) Decreased infarct size, less chamber dilation, and improved hemodynamic conditions have been reported.\(^10\) Two categories of CSCs have been identified. CSCs with predominantly myogenic potential are termed mCSCs. In addition, a subset of human CSCs identified by the cell marker kinase insert domain receptor (KDR) termed vascular progenitor cells (vCSCs) have been shown to form new conductive arteries leading to improved coronary flow and improved ventricular function when injected into immune-suppressed canines at the site of coronary vascular constriction.\(^11\)

We addressed the question of whether intramyocardial injection of CSCs into the chronically infarcted heart would lead to beneficial effects on the late phase of adverse cardiac remodeling. To do this we used autologous cells cultured from cardiac tissue collected at the time of experimental myocardial infarct and then delivered 6 weeks later. We followed the animals for 30 weeks to address the hypothesis that CSCs would favorably alter the late phase of adverse LV remodeling post-MI. In addition, we asked a second question of whether injection of mCSCs in the body of the infarct and vCSCs at the site of coronary ligation would lead to an enhanced recovery of function.

**Methods**

All animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (Eighth Edition, Revised 2010). Our experimental design (Figure 1) consisted of infarct creation, followed by MRI and cell injection at 6 weeks, and randomization to 1 of 3 groups (control, mCSC injection within the body of the infarct and at the left anterior descending coronary artery (LAD) ligation site, and mCSC injection in the body of the infarct and vCSCs given at the LAD ligation site). Animals were allowed to recover for 24 weeks and then reimaged and euthanized.

**Infarct Creation**

Male mongrel dogs aged 7 to 18 months and weighing 17 to 25 kg underwent myocardial infarct creation by open surgical technique with suture ligation of the LAD and diagonal branches under direct visualization. Induction and maintenance anesthesia were accomplished with Propofol (5 mg/kg) and isoflurane (1%–4%).

**Cell Isolation and Culture**

During the initial surgery, a sample of the left atrial appendage was collected, finely divided (<1 mm\(^3\)), and suspended in 15 mL Ham’s F12 medium containing 1 to 3 mg/mL of collagenase NB 4. As previously described\(^12\) and as used in the recent Stem Cell Infusion in Patients with Ischemic Cardiomyopathy (SCIPIO) clinical trial,\(^13\) tissue samples were enzymatically dissociated to obtain single cell suspensions. After digestion, cells were plated in culture dishes containing Ham’s F12 medium supplemented with 10% fetal bovine serum, 100 ng/mL recombinant human basic fibroblast growth factor, 0.2 mmol/L l-glutathione, and 5 mIU/mL human erythropoietin (Sigma). Subsequently, cells were expanded and subjected to immunomagnetic sorting with rabbit anti-kit (Santa Cruz Biotechnology) and magnetic microbeads (CD117 MicroBead kit, Miltenyi) to obtain c-kit\(^{pos}\) CSCs. C-kit\(^{pos}\) cells were further analyzed and sorted by fluorescence-activated cell sorter according to the expression of KDR (KDR Antibody, Abcam Ab2349). C-kit\(^{pos}\) cells and cells positive for c-kit and KDR corresponded to mCSCs and vCSCs, respectively. Importantly, both classes of CSCs were obtained in all animals studied. After enrichment, mCSCs and vCSCs were expanded in F12K medium supplemented with 10% fetal bovine serum. mCSCs were expanded until passage 7 to 8 (P7-P8). Additionally, c-kit and c-kit–KDR positive CSCs (vCSCs) were analyzed by flow-cytometry for the evaluation of their undifferentiated state. Cellular debris and aggregates were gated out based on forward and side scatter. Gating on the signal of the nuclear stain 4′,6-Diamidino-2-phenylindole was used to exclude additional artifacts. Isotype-matched negative controls were used to define the threshold for each specific signal and establish the appropriate gate for positive cells. Data were analyzed with the instrument software. Fluorescence-activated cell sorter analysis was performed with fluorescence-activated cell sorter Aria (Becton Dickinson) or Accuri C6 (Accuri Cytometers) instruments. Approximately 10×10\(^6\) CSCs were obtained from each dog.

![Figure 1. Experimental design from infarct creation through terminal hemodynamics and pathological examination with numbers of animals remaining in study at each time point. CSC indicates cardiac stem cells.](http://circheartfailure.ahajournals.org/doi/abs/10.1161/CIRCHEARTFAILURE.113.003134)
Table. Cardiac Parameters for Control and Cell-Treated Groups at 6 and 30 Weeks Postinfarction

<table>
<thead>
<tr>
<th>Table</th>
<th>Control (n=6)</th>
<th>Treated (n=13)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>6 wk</td>
<td>30 wk</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>20.0 (18.9–22.2)</td>
<td>21.9 (18.8–25.6)</td>
</tr>
<tr>
<td>LVEDV, mL</td>
<td>51.3 (43.3–57.4)</td>
<td>76.1 (72.0–82.4)</td>
</tr>
<tr>
<td>LVESV, mL</td>
<td>78.5 (69.7–86.1)</td>
<td>99.2 (97.1–100.4)</td>
</tr>
<tr>
<td>Infarct size, %</td>
<td>11.7 (8.6–17.4)</td>
<td>9.7 (5.0–11.2)</td>
</tr>
<tr>
<td>Infarct volume</td>
<td>6.2 (4.2–7.6)</td>
<td>4.8 (4.8–7.7)</td>
</tr>
<tr>
<td>LVEF, %</td>
<td>35.2 (27.9–38.7)</td>
<td>26.4 (22.0–31.0)</td>
</tr>
<tr>
<td>LVEDP, mm Hg</td>
<td>21.0 (20.0–23.0)</td>
<td>22.0 (18.0–22.5)</td>
</tr>
</tbody>
</table>

LVEDP indicates left ventricular end-diastolic pressure; LVEDV, left-ventricular end-diastolic volume; LVEF, left-ventricular ejection fraction; and LVESV, left-ventricular end-systolic volume.

Cardiac MRI

Animals were anesthetized via the same protocol for surgery and were studied supine in a 3.0T Cardiac MRI system (Siemens HDx, GE Healthcare) with an 8-element phased-array surface coil. Cardiac MRI study consisted of cine steady-state free precession imaging (typical TR/TE 3.4/1.2 ms, in-plane spatial resolution 1.3×1.5 mm) of LV function and late gadolinium enhancement (LGE) imaging (TR/TE 4.8/1.3 ms, TI 200-300 ms) for myocardial scar. All images were acquired using ECG gating and temporary cessation of mechanical ventilation to minimize cardiac and respiratory motion, respectively. Cine and LGE imaging were obtained in 8 to 14 short-axis planes. A previously described segmented inversion-recovery pulse sequence for LGE imaging was used starting at 15 minutes after a cumulative 0.15 mmol/kg dose of gadolinium-DPTA (Gadopentetate Dimeglumine, Bayer HealthCare, Wayne, NJ). All images were analyzed with specialized software (QMass, Medis, Leiden, the Netherlands). All LGE images were analyzed at a separate session from the interpretation of segmental wall motion. We interpreted LGE as present or absent and quantified the myocardial mass of the LGE by a semiautomated detection method. We followed the 17-segment nomenclature in assigning the coronary distribution of the myocardial segments with abnormal LGE. To quantify the myocardial mass of the LGE, the endocardial and epicardial borders of the short-axis LV on LGE imaging were manually traced. Then the computer-assisted detection algorithm defined LGE as any region with a signal intensity >2 SD above a reference remote myocardial region as previously reported. We expressed LGE mass as both grams of tissue and as a percentage of the LV mass (LGE%). We manually traced epicardial and endocardial borders of matching short-axis cine locations at end-systole and end-diastole to determine the LV ejection fraction (LVEF), end-diastolic volume, end-systolic volume (LVESV), and the LV myocardial mass (end-diastole only). LVEF was measured by standard Simpson’s rule.

Cell Injection

Only animals with a measured infarct size of >5% of LV mass were continued in the study. One to 2 days post-MRI, the animals were sedated and intubated and underwent a second thoracotomy. Angiography was performed to verify the site of LAD ligation to allow for identification of sites for injection. The day of the injections, mCSCs and vCSCs were exposed for 2 hours to insulin-like growth factor-1 and hepatocyte growth factor. After the stimulation treatments, mCSCs and VCSCs were exposed for 2 hours to insulin-like growth factor-1 and hepatocyte growth factor. After the stimulation with growth factors, mCSCs were detached and counted to obtain a single cell solution with a concentration of 1×10^6 cells/mL: 0.8 mL was loaded in each syringe. According to a prespecified block randomization scheme (1:1:1 for 3 groups; control, mCSCs, and mCSCs with vCSCs), cells were delivered in 1 mL syringes labeled for the proximal site and distal site. According to the protocol, 8 injections (80×0.1 mL=80×100,000 cells) were performed in each of the 2 sites of delivery. Operators were blinded to the content of the syringes. Purse-string sutures (3-0 Ethibond) were placed around 2 needle entry sites, one at the proximal LAD ligation sites and the other further down the LAD within the body of the infarct. Utilizing a 25-gauge needle bent by hand at the operating table to ≈45°, the cells were delivered into the myocardium in parallel with the anterior wall without entering the ventricular cavity (Figure 2). Aliquots of cells, or control medium, were delivered in a radial pattern from roughly a 1 o’clock to a 5 o’clock position via separate 0.1 to 0.2 mL injections along each radial line. For each new radius, the needle was redirected without withdrawing the tip from the myocardium. As per the experimental design, groups were designed to include PBS injections at proximal and a distal site, mCSCs at both sites, and vCSCs in the proximal site and mCSCs in the distal site. After completion of

Figure 2. Picture representing infarct model. Red x’s mark sites of coronary ligation of left anterior descending artery and branches. Shaded zone represents infarct area. The arrows show the path of needle insertion and administration of cells radiating from the central needle insertion sites.
delivery, each purse-string suture was closed over the entry site during withdrawal of the needle to limit the escape of cells. The thoracotomy was closed as described above and the animals were allowed to recover with the same pain-monitoring and control procedures.

Terminal Studies
At 30 weeks post-MI, the animals underwent repeat MRI. After 1 to 2 days, they were sedated and placed under general anesthesia. Femoral access was obtained and the animals underwent angiography to document the state of the coronary anatomy. The aortic valve was crossed and baseline LV systolic and end-diastolic pressures were measured. Afterward, the chest was opened, 20,000 units of heparin were given intravenously, and all vessels originating from the aortic arch were ligated. Euthanasia solution (sodium pentobarbital 390 mg/mL and sodium phenytoin 50 mg/mL) was given at 150 mg/kg, and then the heart was arrested in diastole by the injection of potassium chloride, 100 mmol/L, into the LV. The descending aorta was ligated and cannulated, the heart perfused retrograde with normal saline and then with 10% buffered formalin. The perfusion pressure was maintained at 100 mm Hg. The heart was then removed and dissected. The areas of injection were identified by the presence of suture and marked for histological location.

Histology
After photographing, hearts were differentially colored over the anterior surface to grossly identify regions of previous injections. Hearts were then serially transversely sectioned at 0.1 cm intervals from apex to base (6–7 slices), photographed, and the volumes of associated scar estimated (Figure 3). Histology sections were sampled from the basal face of each slice, with sections bridging both injected and noninjected portions of the specimen. Routine hematoxylin and eosin staining, as well as Masson’s trichrome staining, was performed on 10-µ-thick sections. Immunohistochemistry was performed on 5- to 10-µ-thick formalin-fixed, paraffin-embedded tissue sections using antihuman specificity antibodies unless otherwise indicated; internal control staining demonstrated adequate cross-reactivity of the canine tissues (see online-only Data Supplement for specifics). Tissues were analyzed in a blinded fashion, without knowledge of the nature of the injected cells or whether recipient hearts received control saline only.

Statistics
Results are expressed using the median and interquartile range. The primary planned comparison in the study was LVESV change in the control versus combined cell-treated group with secondary analyses of other MRI parameters. Intragroup analyses (control and treated 6 week versus 30 week) were analyzed with Wilcoxon signed-rank tests. For the primary intergroup comparisons (control versus treated and mCSC versus mCSV/vCSC, change over time), data were analyzed by comparing the changes from baseline using the Wilcoxon rank-sum test utilizing STATA data analysis and statistical software. Similar comparisons were performed within the cell-treated groups comparing mCSC versus mCSV/vCSC groups.

Results
Twenty-eight animals underwent initial MI (Figure 1). Three animals with a 6-week MI size < 5% were excluded before randomization. Five animals died before cell injection (2 during the acute infarction and 3 died at postoperative days 15, 16, and 18, respectively, without apparent previous symptoms). Of the 20 randomized animals, 19 completed the protocol through the cell injection and terminal hemodynamics and

![Figure 3](image-url). Representative photograph of a serially transversely sectioned heart revealing antero-apical infarction.

![Figure 4](image-url). Left-ventricular end-systolic volume (LVESV) over time in both control and cell-treated animals. Wilcoxon signed-rank tests were performed to analyze the data within each group, and P values are provided on chart. Using the Wilcoxon rank-sum test, the control group was compared with the cell-treated group showing a P value of 0.01. Shaded zone shows normal values. Boxplots show the median and interquartile range for each time point.

![Figure 5](image-url). Left-ventricular end-diastolic volume (LVEDV) over time in both control and cell-treated animals. Wilcoxon signed-rank tests were performed to analyze the data within each group, and P values are provided on chart. Using the Wilcoxon rank-sum test, the control group was compared with the cell-treated group showing a P value of 0.14. Shaded zone shows normal values. Boxplots show the median and interquartile range for each time point.
MII. One animal (mCSC group, initial infarct size of 14.7%, EF 25%) died suddenly at postoperative day 131.

Control Group
At 6 weeks postinfarct, LVEF was markedly reduced and the ventricular volumes increased from normal canine values19–22 (Table). In the control group, there was progressive further dilatation of the ventricle from 6 weeks to 30 weeks with increases in LVESV (median [interquartile range], 51.3 [43.3–57.4] mL to 76.1 [72.0–82.4] mL; P=0.03; Figure 4) and LV end-diastolic volume (78.5 mL [69.7–86.1] to 99.2 [97.1–100.4] mL; P=0.03; Figure 5). LVEF at 6 weeks postinfarct was reduced 5.4 mL (4.4–7.1) at 6 weeks to 4.4 mL (2.9–5.0) at 30 weeks (P=0.03; Figure 6). Infarct volume fell from 6.2 mL (5.0–11.2) at 30 weeks to 4.4 mL (2.9–5.0) at 30 weeks (P=0.03). Boxplots show the median and interquartile range for each time point.

CSC Therapy
The 6-week postinfarct values for LVEF and chamber volumes for the cell-treated animals were similar to the control group (Table). However, in the cell-treated animals, the increase in LVESV was attenuated (42.6 mL [38.5–50.5] mL to 56.1 mL [50.3–63.0]; P=0.01 versus control, Figure 4). There was a nonsignificant attenuation in the increase in LV end-diastolic volume (64.8 mL [60.7–71.3] to 83.5 mL [74.7–90.8]; P=0.14 versus control; Figure 5). Unlike the control group, the ejection fraction remained stable (30.5% [28.4–33.4] to 32.9% [28.6–36.9]; P=0.04 versus control; Figure 6). As with control animals, the infarct size fell over time in the cell-treated group (10.9% [9.8–12.5] to 7.3% [6.5–8.8]; P=0.002; P=NS compared with control group). LVEF at 6 weeks postinfarct was reduced 5.4 mL (4.4–7.1) at 6 weeks to 4.4 mL (2.9–5.0) at 30 weeks (P=0.004; P=NS compared with control group).

A secondary aim of the study was to examine whether injection of mCSCs in the body of the infarct and vCSCs at the site of coronary ligation would lead to an enhanced recovery of function compared with mCSCs at both sites. Examination of MRI results did not reveal any between group differences comparing animals treated with mCSCs at both sites (n=6) and those treated with vCSCs (n=7) at the upper injection site and mCSCs at the lower site.

Pathology
All hearts had overt well-healed myocardial infarcts with areas of scarring showing variable degrees of dense fibrosis, focally admixed with adipose tissue and residual adjacent hypertrophied myocytes, and with scattered primarily mononuclear cell inflammation; epicardial injection sites were identifiable by the presence of suture and foreign body granuloma formation. Vascularity ranged from sparse, focal capillary and arteriolar proliferation, to larger well-developed postinflammatory vessels. There was no relationship identified between the nature of the injections (control versus Cell-treated preparations or between CSC groups) and the characteristics, density, or distribution of fibrosis, adipose tissue, or vessels.

In 3 animals, distinct epicardial-based collections of cells were identified. These collections of cells were identified in 2 animals that received control PBS injections only, and in 1 animal receiving mCSCs and vCSCs. In all instances, the cells appeared to originate adjacent to sutures used to seal the injection sites.

One lesion in a control animal measured 0.5 cm in greatest dimension, and was not grossly apparent, merging imperceptibly with adjacent fibrosis; the other case in a control animal presented as a firm, rubbery, expansile epicardial-based lesion measuring 4.5x4x3.5 cm (online-only Data Supplement). The large infiltrating cells did not stain with reagents specific for α-actinin, sarcomeric actin, desmin, or HHF35, although entrapped cardiomyocytes and smooth muscle cells within vessels could be identified. These cells also did not show immunohistochemical staining for CD34, cytoketarin, von Willebrand factor, CD19, CD20, CD45, CD163, c-Kit, S100, or myf-4. After exhaustive work-up, the lesions can best be described as atypical histiocytoid proliferations of uncertain biological potential. Because these atypical collections of cells occur at the suture sites and after PBS injection only, it is most likely that these lesions represent an unusual reactive lesion resulting from the experimental manipulations.

In addition, one of the experimental postinfarct animals receiving mCSCs and vCSCs also exhibited a subpopulation of infiltrating cells that by immunofluorescence and immunohistochemistry expressed markers consistent with immature cardiomyocytes, including cardiac α-actinin, sarcomeric actin, desmin, and HHF35; cells within these foci also occasionally expressed Nkx2.5, and very rarely connexin 43 and c-Kit (CD117). These cells did not show immunohistochemical staining for CD34, cytoketarin, von Willebrand factor, CD19, CD20, CD45, CD163, c-Kit, S100, or myf-4. After exhaustive work-up, the lesions can best be described as atypical histiocytoid proliferations of uncertain biological potential. Because these atypical collections of cells occur at the suture sites and after PBS injection only, it is most likely that these lesions represent an unusual reactive lesion resulting from the experimental manipulations.

Discussion
Canine models of ischemia, MI, and heart failure have been previously reported. However, the presence of vigorous collateral...
circulation in the canine has been considered to limit their use as models for progressive adverse ventricular remodeling. Others have approached this limitation by causing repetitive global infarcts with injection of microspheres.\textsuperscript{21} We report the development of a canine model of chronic MI with continued adverse remodeling in the late phase (6–30 weeks). At 6 weeks, animals showed depressed EF in the range of 30% to 35% (normal range 50%–70%)\textsuperscript{19,20} and systolic and diastolic volumes. Other groups have reported large infarct creation in the canine with ligation of the proximal LAD, diagonals, and collaterals from other territories, but have limited the duration of follow-up to 12 weeks.\textsuperscript{24} In our study of large infarcts, we confirm adverse LV remodeling at 6 weeks and 30 weeks, demonstrating continued increase in LV volumes and a further nonsignificant decrease in EF. The choice of the canine model in this study was made because of the well-characterized nature of CSCs in this species. It is important to note, however, that other species of large animals have been used as models of ischemic heart failure, including pigs and sheep.\textsuperscript{25} Pig MI models have been used and have the advantage of a lesser developed collateral circulation compared with dogs. Similarly, selective ligation of coronary arteries in the sheep has been used to study heart failure and has found particular value in the creation of models of ischemic mitral regurgitation. The control group in our study fulfilled our objective by demonstrating progressive adverse LV remodeling.

We now report that in this canine model of chronic infarction and late adverse ventricular remodeling, the direct injection of myocardial CSCs leads to a durable improvement in ventricular size and EF. Most previous animal studies have focused on the use of stem cells in the acute or subacute phase of MI. However, the cardiovascular milieu is markedly different in the chronic infarct in terms of inflammation, cytokines, growth factors, and adhesion molecules, possibly having an effect on the success of stem cells to engraft and flourish. Tang et al\textsuperscript{26} investigated the effect of CSC injection in the chronically infarcted rat heart using a model of cell injection 30-days postinfarct. A single clonogenic c-kit\textsuperscript{pos} cell expressing enhanced green fluorescent protein was used to develop a c-kit\textsuperscript{pos}-enhanced green fluorescent protein\textsuperscript{mCherry} clone, which was used in these studies. At 35-days postinjection, the authors found improvement in LV function, with an increase in viable myocardium and less fibrosis associated with injection of CSCs. Previous studies of CSC injection in the canine model have focused on injection after acute MI and have used cross-species cells in immune-suppressed animals with relatively short follow-up.\textsuperscript{11} We studied the effect of autologous stem cell injection in the chronically infarcted canine heart (6 weeks after coronary ligation) at a time point when adverse remodeling was already apparent and found that the injection of \( \approx 1.6 \) million CSCs had a favorable effect on the late phase of cardiac remodeling in the chronically infarcted canine heart.

A common strategy used in animal models of cell therapy for myocardial regeneration is the use of cross-species cells, typically human cells in an animal recipient. This strategy allows for the tracking of cells through immuno-cytochemical methods to determine cell fate. However, this practice requires the use of immunosuppression to limit xenogenic cell rejection. In turn, this limits the duration of experiments and, thus, little is known about the durability of beneficial effects of cardiac regenerative therapies. Use of autologous cells circumvents this problem and has been the practice in human studies of stem cells in cardiac repair. We used autologous CSCs in this study to extend the period of observation to 30 weeks and found a significant improvement in LV volumes and LVEF compared with control at this time point, suggesting a durable result from CSC injection.

There are several human trials that have investigated the use of intracoronary autologous BMCs in the setting of acute MI (within 1 week) showing improvement in LVEF. However, the recently published Late TIME (Transplantation In Myocardial Infarction Evaluation) trial investigated the use of BMCs at 2 to 3 weeks postinfarction and found no beneficial effects on global or regional function.\textsuperscript{27} Other investigations have focused on cardiac-derived progenitor cells. The recently published CADUCEUS (Cardiosphere-derived Autologous Stem Cells to Reverse Ventricular Dysfunction) phase 1 trial used cardiosphere-derived cells cultured from endomyocardial biopsy specimens from patients with ischemic cardiomyopathy after recent MI.\textsuperscript{28} These cells, notable for the presence of the cell-surface marker CD105, were given via intracoronary injection to the region of infarct. At 6 months, there was a reduction in scar mass as assessed by MRI, although no change in LVEF or ventricular volumes. The SCIPIO trial (a phase 1 study) investigated the use of c-kit\textsuperscript{pos} CSCs in the treatment of patients with ischemic cardiomyopathy 4 months postcardiac surgical bypass.\textsuperscript{13} In this group of patients with chronic ischemic dysfunction, intracoronary mCSCs improved LVEF from 30.3±1.9% before mCSC infusion to 38.5±2.8% 4 months after infusion. In addition to the species and other obvious differences between the SCIPIO trial and our animal study, our model was the dynamic phase of adverse remodeling after experimental infarction as opposed to the stable reduced EFs in patients undergoing elective revascularization enrolled in the clinical trial. Although we did not observe a statistically significant improvement in EF in our animal study, we consider the attenuation of adverse remodeling using autologous CSCs in our coronary ligation model to be supportive of beneficial cardiac effects of these cells.

The durability of effect of stem cell cardiac therapy in humans is also an important issue. For example, in the BOne MarrOw Transfer to Enhance ST-Elevation Infarct Regeneration (BOOST) trial, patients underwent intracoronary infusion of unselected, autologous, BMCs 4.8±1.3 days after having undergone successful percutaneous coronary intervention for acute MI. Using cardiac MRI to evaluate ventricular function, the authors reported a statistically significant improvement in ventricular function in the patients assigned to BMC infusion at 6±1 month after random treatment.\textsuperscript{29} However, at the 18-month evaluation, the difference between groups was no longer significant.\textsuperscript{30} These findings raise the important issue of durability of results from single administration of stem cells, emphasizing the need for long-term studies.

A secondary aim of the current study was to examine the potential effect of preferentially delivering vCSCs at the proximal site of injection. Bearzi et al\textsuperscript{11} identified a human subset of CSCs committed to a vascular lineage and identified by the presence of the cell marker KDR (vCSCs). These human cells (50,000), when injected into canine myocardium at the site of an experimentally induced critical stenosis, were found to produce small, medium, and large coronary arteries and led to functional improvement of ischemic myocardium. In our
study, there was no signal of a difference in MRI measures of cardiac function, volumes, or in tissue examination by a cardiac pathologist. Given the small number of overall subjects in the current study (6 with mCSCs, 7 with vCSCs at upper zone), we cannot exclude a possible salubrious effect of these cells that was not statistically identifiable in this small cohort. In addition, the canine myocardium has a well-established capacity for development of vigorous collaterals, which may make this model not as predictive of the potential of a specific vascular progenitor cell in ischemic regions in humans.

The atypical histiocytoid proliferations of uncertain biological potential identified at the site of injections in 2 animals receiving control PBS injections and in 1 animal who received mCSCs and vCSCs were an unexpected finding. These unusual reactions are interpreted as likely sequelae of experimental manipulation and raise the concern for potential unintended biological consequences of direct myocardial injection. We chose to utilize a method of direct injection of CSCs into the myocardium through an epicardial approach. Other investigators have used an endovascular approach with specialized catheters for injection and usually in conjunction with electromechanical mapping. Even more intriguing is the recent evidence that a direct coronary injection route leads to cell engraftment in animals and functional improvement in both animals and humans. Such an approach has obvious appeal attributable to its less invasive approach and specifically in our study may have led to less inflammatory reactions.

Limitations
The chief limitation of the current study is the lack of ability to track cells and to, therefore, comment on mechanisms of improvement in remodeling. Previous studies of CSCs in animal models of infarct have demonstrated improvement in cardiac function attributable to the differentiation of delivered cells into functioning myocytes. Some studies also suggest beneficial paracrine effects, including the capacity of delivered cells to stimulate endogenous CSCs. The use of autologous cells allowed for the long duration of follow-up in these animals and was the principal aim of this study. The use of cross-species cells would have allowed for tracking of cells by immunohistochemistry, but the immune-suppression necessary for such a strategy was not felt to be practical for such a long period. The current study was designed to pragmatically address whether CSC therapy could alter the late phase of adverse ventricular remodeling after MI and was not designed to allow determination of specific mechanistic insights. Therefore, it is impossible to ascribe the favorable effects on LV remodeling to engrafted cells or combined to paracrine effects. This study was not designed to compare different modalities or techniques within the field of regenerative therapy, but rather to study the effect of CSCs in this model. Other limitations of the study include lack of baseline (before infarction) and interim time points for study. These time points were not studied to limit the anesthetic exposures of the animals.

Conclusions
We report a large animal model of late (6–30 week) LV remodeling after MI with increases in LVESV and in LV end-diastolic volume and a reduction in EF. In this study, we demonstrated that intramyocardial injection of autologous CSCs favorably altered the biology of this process and attenuated long-term adverse cardiac remodeling and preserved LV function.

Sources of Funding
This study was supported by NIH P20 HL101866-01 Watkins Cardiovascular Discovery Award (R.G.). It was also supported by a generous gift from Ken and Pixley Schiciano.

Disclosures
Dr Welt serves on a scientific advisory board for Medtronic Inc. Dr Welt has research grants and serves as a consultant to Volcano Corporation. The other authors have no conflicts to report.

References
Stem cell therapy for regeneration of the damaged myocardium has great potential and has already been tested in early phase clinical trials in humans. Yet much remains to be answered in the field. Questions include what type of cell is best suited and under what conditions, what are the proper dosages and frequency of cell administration, and what is the best route of administration? One pressing issue raised by earlier clinical efforts is whether cells have a durable impact on recovery of myocardial function. This has not been studied extensively in animal models. In this article, we sought to better understand the durability of effect of cardiac stem cell administration (c-kit–positive cells) by examining the impact of intramyocardial injection of these cells in the chronically infarcted canine myocardium. We examined the outcomes at 24 weeks postinjection, a time point much longer than previously investigated. We found that even at this late time point, intramyocardial injection of cardiac progenitor cells attenuated the negative remodeling associated with myocardial infarction and maintained ejection fraction. These findings are all the more interesting in light of the SCIPIO trial, a Phase 1 study investigating the use of the same c-kit–positive cardiac stem cells in the treatment of patients with ischemic cardiomyopathy 4 months postcardiac surgical bypass. In this group of patients with chronic ischemic dysfunction, intracoronary cardiac stem cells substantially improved left-ventricular ejection fraction. Large animal models and studies, such as the one presented here, are vital to effectively plan for definitive trials of regenerative therapies in humans.
Effect of Cardiac Stem Cells on Left-Ventricular Remodeling in a Canine Model of Chronic Myocardial Infarction

Circ Heart Fail. 2013;6:99-106; originally published online December 4, 2012; doi: 10.1161/CIRCHEARTFAILURE.112.972273
Circulation: Heart Failure is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3289. Online ISSN: 1941-3297

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circheartfailure.ahajournals.org/content/6/1/99

Data Supplement (unedited) at:
http://circheartfailure.ahajournals.org/content/suppl/2012/12/04/CIRCHEARTFAILURE.112.972273.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Heart Failure can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Heart Failure is online at:
http://circheartfailure.ahajournals.org//subscriptions/
Supplemental Materials

Primary antibodies were reacted at the indicated dilutions at room temperature for 40-60 minutes or overnight at 4°C; secondary reagents were DAKO Envision mouse or rabbit antibodies (Carpinteria, CA) incubated at 1:100 dilution for 30 minutes at room temperature. Immunohistochemical staining for CD34 (anti-human epitope), HHF35 (muscle-specific actin), Ki-67, c-Kit (CD117), CD45, or S100 was performed without antigen retrieval; immunohistochemical staining for desmin, CD163, CD34 (anti-canine epitope), von Willebrand factor (vWF), cytokeratin, or myogenin (myf-4 transcription factor) was performed after antigen retrieval using citrate buffer pressure cooking. Anti-desmin antibody (Sigma, St. Louis, MO) was incubated at 1:5000 dilution; anti-HHF antibody (DAKO) was incubated at 1:400; anti-CD34 antibody (DAKO) or anti-canine CD34 antibody (BioLegend, San Diego, CA) was incubated at 1:400 or 1:50, respectively; anti-cytokeratin antibody (MyBioSource, San Diego, CA) was incubated at 1:300 dilution; anti-canine CD45 antibody (AbDSerotec, Raleigh, NC or Leukocyte Antigen Biology Laboratory, Davis, CA) was incubated at 1:10-1:1000 dilutions; anti-canine vWF antibody (LifeSpan BioSciences, Seattle, WA) was incubated at 1:4000 dilution, anti-CD163 antibody (Novocastra, Leica Microsystems, Inc. Buffalo Grove, IL) was incubated at 1:250; anti-CD117 antibody (c-Kit; DAKO) was incubated at 1:250; anti-S100 antibody (DAKO) was incubated at 1:1000; anti-myogenin antibody was incubated at 1:50; anti-Ki-67 antibody (DAKO) was incubated at 1:250.
Figure 1. Representative histology (40X) of scars at the sites of injection in animals receiving myocardial stem cells (Panel A), or phosphate-buffered saline only (Panel B). Regardless of the nature of injection, there was variably dense fibrosis, focally admixed with adipose tissue and residual adjacent hypertrophied myocytes, with scattered primarily mononuclear cell inflammation; epicardial injection sites (*) were identifiable by the presence of suture and foreign body granuloma formation.
Figure 2. Gross (A) and microscopic (B) images from an animal that received only a saline injection. There is a 4.5 cm infiltrative nodule of large irregular cells with irregularly clumped chromatin and an associated mixed inflammatory cell infiltrate. The infiltrating cells did not stain with reagents specific for α-actinin, sarcomeric actin, desmin, or HHF35, although entrapped cardiomyocytes and smooth muscle cells within vessels could be identified. These cells also did not show immunohistochemical staining for CD34, cytokeratin, vWF, CD19, CD20, CD45, CD163, c-Kit, S100, or myf-4. B, 400X.
Figure 3. FACS analysis of canine c-kit positive cardiac stem cells. SSC, side scatter.